In Brief: Aprogenex/Centocor
This article was originally published in The Gray Sheet
Executive Summary
Aprogenex/Centocor: Ink product development and licensing agreement under which Centocor obtains "certain worldwide rights" to Aprogenex' RIGHTechnology (rapid intact gene hybridization technology) in return for an upfront licensing fee, milestone payments and royalties on commercial products using the technology. Centocor will be responsible for the development, regulatory approvals and marketing of products. The agreement is part of Houston-based Aprogenex' effort to combine its DNA probe-based technology with leading cell separation companies ("The Gray Sheet" Sept. 2, I&W-7)...